Compare ASTRAZENECA PHARMA with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ELDER PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ELDER PHARMA ASTRAZENECA PHARMA/
ELDER PHARMA
 
P/E (TTM) x 101.0 -0.2 - View Chart
P/BV x 28.5 0.1 28,201.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ELDER PHARMA
Jun-14
ASTRAZENECA PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278380 336.3%   
Low Rs883188 469.5%   
Sales per share (Unadj.) Rs228.4491.2 46.5%  
Earnings per share (Unadj.) Rs10.4-3.2 -325.7%  
Cash flow per share (Unadj.) Rs16.314.4 112.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.8376.5 26.2%  
Shares outstanding (eoy) m25.0020.54 121.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.70.6 818.1%   
Avg P/E ratio x104.2-89.3 -116.8%  
P/CF ratio (eoy) x66.419.7 337.1%  
Price / Book Value ratio x10.90.8 1,450.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0085,833 463.0%   
No. of employees `0001.4NA-   
Total wages/salary Rs m1,5352,179 70.5%   
Avg. sales/employee Rs Th4,210.9NM-  
Avg. wages/employee Rs Th1,132.2NM-  
Avg. net profit/employee Rs Th191.1NM-  
INCOME DATA
Net Sales Rs m5,71010,089 56.6%  
Other income Rs m123257 47.7%   
Total revenues Rs m5,83310,346 56.4%   
Gross profit Rs m463-792 -58.5%  
Depreciation Rs m147361 40.8%   
Interest Rs m02,756 0.0%   
Profit before tax Rs m438-3,653 -12.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m179125 142.9%   
Profit after tax Rs m259-65 -396.5%  
Gross profit margin %8.1-7.8 -103.3%  
Effective tax rate %40.8-3.4 -1,192.2%   
Net profit margin %4.5-0.6 -700.5%  
BALANCE SHEET DATA
Current assets Rs m3,2099,240 34.7%   
Current liabilities Rs m2,0709,998 20.7%   
Net working cap to sales %20.0-7.5 -265.8%  
Current ratio x1.60.9 167.8%  
Inventory Days Days7246 156.2%  
Debtors Days Days3560 58.3%  
Net fixed assets Rs m79010,124 7.8%   
Share capital Rs m50206 24.3%   
"Free" reserves Rs m2,4195,582 43.3%   
Net worth Rs m2,4697,734 31.9%   
Long term debt Rs m04,889 0.0%   
Total assets Rs m4,60522,882 20.1%  
Interest coverage xNM-0.3-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.20.4 281.2%   
Return on assets %5.611.8 47.8%  
Return on equity %10.5-0.8 -1,241.7%  
Return on capital %17.722.3 79.5%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m300307 97.7%   
Fx outflow Rs m2,015125 1,608.1%   
Net fx Rs m-1,715181 -946.1%   
CASH FLOW
From Operations Rs m8811,754 0.7%  
From Investments Rs m-94-561 16.7%  
From Financial Activity Rs mNA-6,762 0.0%  
Net Cashflow Rs m-64,432 -0.1%  

Share Holding

Indian Promoters % 0.0 39.6 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 7.5 4.0%  
FIIs % 15.7 16.8 93.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 36.1 25.2%  
Shareholders   12,856 16,479 78.0%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   NOVARTIS  TORRENT PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; Metal Stocks Rally(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 1.2% while the Hang Seng is up 2.1%.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

Make the Most of the Smallcap Rebound with These Stocks(Profit Hunter)

Dec 3, 2019

Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.

What Is the IPO Euphoria Signaling Us About the Markets?(The 5 Minute Wrapup)

Dec 2, 2019

2019 will be remembered as the year of great money-making IPOs...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Dec 13, 2019 11:19 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS